Suppr超能文献

人源脑肿瘤干细胞的增殖与耐药性研究。

Study on the proliferation and drug-resistance of human brain tumor stem-like cells.

机构信息

Neurosurgery Institute, Key Laboratory on Brain Function Repair and Regeneration of Guangdong, Southern Medical University, Guangzhou, 510282, China.

出版信息

Cell Mol Neurobiol. 2010 Aug;30(6):955-60. doi: 10.1007/s10571-010-9525-9. Epub 2010 Jun 6.

Abstract

Brain tumor stem-like cells (BTSLCs) have been implied to play an important role in genesis and development of glioma. However, their characteristics on proliferation and drug-resistance are uncertain thoroughly. In this experiment, some of the biological characteristics about BTSLCs were explored. Twenty cases of different grades of human glioma tissues were obtained from clinic. The primary glioma cells were collected and CD133(+) cells from them were purified by magnetic cell sorting assay. The BTSLCs were identified by testing the expression of CD133, Nestin, NSE, and GFAP, along with the culture process. WST-8 assay kit was used to evaluate the proliferating situation of CD133(+) cells in the different grade gliomas, and to compare the drug-resistance between the CD133(+) and CD133( - ) cells in the medium containing different concentrations of teniposide (VM-26). The results showed that the CD133(+) cells could regenerate by self-renewal, then generate and different into NSE(+) and GFAP(+) cells, respectively. CD133(+) cells in the high grade of gliomas showed the faster generation than the ones in the low grade. The number of survived CD133(+) cells in the medium containing VM-26 was much more than the CD133(-) ones in it. Therefore, it was implied that the CD133(+) BTSLCs existed in the glioma tissues possessed the more tolerant ability to the VM-26, and could proliferate much more easily in the high-grade glioma.

摘要

脑肿瘤干细胞样细胞(BTSLCs)被认为在神经胶质瘤的发生和发展中起重要作用。然而,其增殖和耐药特性尚不完全清楚。本实验探索了 BTSLCs 的一些生物学特性。从临床获得 20 例不同级别人胶质瘤组织,通过磁珠细胞分选法分离并培养原代胶质瘤细胞,从中分离出 CD133(+)细胞。通过检测 CD133、Nestin、NSE 和 GFAP 的表达以及培养过程来鉴定 BTSLCs。WST-8 试剂盒用于评估不同级别胶质瘤中 CD133(+)细胞的增殖情况,并比较含不同浓度替尼泊苷(VM-26)的培养基中 CD133(+)和 CD133(-)细胞的耐药性。结果显示,CD133(+)细胞可通过自我更新再生,并分别分化为 NSE(+)和 GFAP(+)细胞。高级别胶质瘤中的 CD133(+)细胞比低级别胶质瘤中的细胞增殖更快。含 VM-26 的培养基中存活的 CD133(+)细胞数量明显多于其中的 CD133(-)细胞。因此,提示胶质瘤组织中存在对 VM-26 耐药性更强、更容易在高级别胶质瘤中增殖的 CD133(+) BTSLCs。

相似文献

1
6
Identification of A2B5+CD133- tumor-initiating cells in adult human gliomas.成人人类胶质瘤中A2B5+CD133-肿瘤起始细胞的鉴定
Neurosurgery. 2008 Feb;62(2):505-14; discussion 514-5. doi: 10.1227/01.neu.0000316019.28421.95.

本文引用的文献

3
Malignant gliomas in adults.成人恶性胶质瘤
N Engl J Med. 2008 Jul 31;359(5):492-507. doi: 10.1056/NEJMra0708126.
7
Identification and expansion of the tumorigenic lung cancer stem cell population.致瘤性肺癌干细胞群体的鉴定与扩增。
Cell Death Differ. 2008 Mar;15(3):504-14. doi: 10.1038/sj.cdd.4402283. Epub 2007 Nov 30.
10
Identification and expansion of human colon-cancer-initiating cells.人结肠癌起始细胞的鉴定与扩增。
Nature. 2007 Jan 4;445(7123):111-5. doi: 10.1038/nature05384. Epub 2006 Nov 19.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验